Contact Us

Taiwan Toxin OBI-858 Development Progress

A Long-Acting Botulinum Toxin Developed for the Next Generation of Aesthetic and Therapeutic Needs.

OBI-858 is the first clinical product developed from Obigen Pharma's proprietary 760 kDa long-acting botulinum toxin platform. Currently advancing through clinical development in both Taiwan and the United States, OBI-858 serves as the foundation for expanding into a broad range of aesthetic and therapeutic indications, building a globally competitive botulinum toxin platform.

Platform
Indication
Current Progress
OBI-858
Glabellar line (TW)
Research
Preclinical
Phase I
Phase II
Phase III
OBI-858
Glabellar line (US)
Research
Preclinical
Phase I
Phase II
Phase III
OBI-858
Upper limb spasticity
Research
Preclinical
Phase I
Phase II
Phase III
OBI-858
Others
Research
Preclinical
Phase I
Phase II
Phase III
PlatformOBI-858
IndicationGlabellar line (TW)
PlatformOBI-858
IndicationGlabellar line (US)
PlatformOBI-858
IndicationUpper limb spasticity
PlatformOBI-858
IndicationOthers
＊Cervical dystonia, chronic migraine, Overactive bladder, hyperhidrosis

Development Progress

  • Phase III clinical trial for glabellar lines currently underway in Taiwan.
  • Phase II clinical trial for glabellar lines currently underway in the United States.
  • Clinical studies have demonstrated the potential for efficacy lasting up to six months.
  • Actively expanding development across both aesthetic and therapeutic indications.

Vision:

More than the next botulinum toxin product. The next global botulinum toxin platform.